Cargando…
C-reactive protein: a target for therapy to reduce inflammation
C-reactive protein (CRP) is well-recognized as a sensitive biomarker of inflammation. Association of elevations in plasma/serum CRP level with disease state has received considerable attention, even though CRP is not a specific indicator of a single disease state. Circulating CRP levels have been mo...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10410079/ https://www.ncbi.nlm.nih.gov/pubmed/37564640 http://dx.doi.org/10.3389/fimmu.2023.1237729 |
_version_ | 1785086380136726528 |
---|---|
author | Rizo-Téllez, Salma A. Sekheri, Meriem Filep, János G. |
author_facet | Rizo-Téllez, Salma A. Sekheri, Meriem Filep, János G. |
author_sort | Rizo-Téllez, Salma A. |
collection | PubMed |
description | C-reactive protein (CRP) is well-recognized as a sensitive biomarker of inflammation. Association of elevations in plasma/serum CRP level with disease state has received considerable attention, even though CRP is not a specific indicator of a single disease state. Circulating CRP levels have been monitored with a varying degree of success to gauge disease severity or to predict disease progression and outcome. Elevations in CRP level have been implicated as a useful marker to identify patients at risk for cardiovascular disease and certain cancers, and to guide therapy in a context-dependent manner. Since even strong associations do not establish causality, the pathogenic role of CRP has often been over-interpreted. CRP functions as an important modulator of host defense against bacterial infection, tissue injury and autoimmunity. CRP exists in conformationally distinct forms, which exhibit distinct functional properties and help explaining the diverse, often contradictory effects attributed to CRP. In particular, dissociation of native pentameric CRP into its subunits, monomeric CRP, unmasks “hidden” pro-inflammatory activities in pentameric CRP. Here, we review recent advances in CRP targeting strategies, therapeutic lowering of circulating CRP level and development of CRP antagonists, and a conformation change inhibitor in particular. We will also discuss their therapeutic potential in mitigating the deleterious actions attributed to CRP under various pathologies, including cardiovascular, pulmonary and autoimmune diseases and cancer. |
format | Online Article Text |
id | pubmed-10410079 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-104100792023-08-10 C-reactive protein: a target for therapy to reduce inflammation Rizo-Téllez, Salma A. Sekheri, Meriem Filep, János G. Front Immunol Immunology C-reactive protein (CRP) is well-recognized as a sensitive biomarker of inflammation. Association of elevations in plasma/serum CRP level with disease state has received considerable attention, even though CRP is not a specific indicator of a single disease state. Circulating CRP levels have been monitored with a varying degree of success to gauge disease severity or to predict disease progression and outcome. Elevations in CRP level have been implicated as a useful marker to identify patients at risk for cardiovascular disease and certain cancers, and to guide therapy in a context-dependent manner. Since even strong associations do not establish causality, the pathogenic role of CRP has often been over-interpreted. CRP functions as an important modulator of host defense against bacterial infection, tissue injury and autoimmunity. CRP exists in conformationally distinct forms, which exhibit distinct functional properties and help explaining the diverse, often contradictory effects attributed to CRP. In particular, dissociation of native pentameric CRP into its subunits, monomeric CRP, unmasks “hidden” pro-inflammatory activities in pentameric CRP. Here, we review recent advances in CRP targeting strategies, therapeutic lowering of circulating CRP level and development of CRP antagonists, and a conformation change inhibitor in particular. We will also discuss their therapeutic potential in mitigating the deleterious actions attributed to CRP under various pathologies, including cardiovascular, pulmonary and autoimmune diseases and cancer. Frontiers Media S.A. 2023-07-26 /pmc/articles/PMC10410079/ /pubmed/37564640 http://dx.doi.org/10.3389/fimmu.2023.1237729 Text en Copyright © 2023 Rizo-Téllez, Sekheri and Filep https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Rizo-Téllez, Salma A. Sekheri, Meriem Filep, János G. C-reactive protein: a target for therapy to reduce inflammation |
title | C-reactive protein: a target for therapy to reduce inflammation |
title_full | C-reactive protein: a target for therapy to reduce inflammation |
title_fullStr | C-reactive protein: a target for therapy to reduce inflammation |
title_full_unstemmed | C-reactive protein: a target for therapy to reduce inflammation |
title_short | C-reactive protein: a target for therapy to reduce inflammation |
title_sort | c-reactive protein: a target for therapy to reduce inflammation |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10410079/ https://www.ncbi.nlm.nih.gov/pubmed/37564640 http://dx.doi.org/10.3389/fimmu.2023.1237729 |
work_keys_str_mv | AT rizotellezsalmaa creactiveproteinatargetfortherapytoreduceinflammation AT sekherimeriem creactiveproteinatargetfortherapytoreduceinflammation AT filepjanosg creactiveproteinatargetfortherapytoreduceinflammation |